Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $353.5452W HIGH $615.00
Volume
441.25 K
Value Traded
187.15 M
Short % Float
9.86%
Days to Cover
7.6
-1.25%Week
-7.05%1 Month
-18.57%3 Month
-18.16%6 Month
+300.88%5 Year
+47.94%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
9.93 B
EPS (TTM)
-6.69
P/E Ratio
-
Ent. Value
9.31 B
Total Shares
23.23 M
Float Shares
21.66 M
Insiders
6.77%
Institutions
102.80%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
MDGL Catalyst Timeline
Dated clinical, regulatory and corporate events for Madrigal Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Madrigal Pharmaceuticals, Inc.
467Total events
7Upcoming
96Tier-1 (high impact)
2016 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationResmetiromApprovedPresentation
18 Madrigal abstracts accepted at AASLD Liver Meeting, Nov. 5-9, 2026
MASHsource ↗
▲RWE DataResmetiromApprovedClinical Data
Real-world data at AASLD 2026 show liver stiffness improvement/stabilization with Rezdiffra
MASH with moderate to advanced liver fibrosis (F2-F3)source ↗
●Poster PresentationResmetiromApprovedPresentation
Real-world Rezdiffra studies presented at AASLD 2026 The Liver Meeting
MASHsource ↗
●Quarterly UpdateResmetiromApprovedCorporate
Madrigal reports Q3 2026 financial results and corporate updates
MASHsource ↗
●Equity OfferingCorporate
Grants of inducement equity awards to 26 new employees under Nasdaq Rule 5635(c)(4)
▲Subgroup AnalysisResmetiromApprovedClinical Data
Secondary analysis showed consistent Rezdiffra efficacy across common MASH genetic risk variants (PNPLA3, HSD17B13, TM6SF2, MTARC1, MBOAT7)
MASHsource ↗
▲PublicationResmetiromApprovedPresentation
Publication in Journal of Hepatology of pre-specified secondary genetic-variant analysis from MAESTRO-NASH
MASHsource ↗
▲Secondary Endpoint DataResmetiromApprovedClinical Data
Consistent histology, MRI-PDFF and biomarker responses across PNPLA3, HSD17B13, TM6SF2, MTARC1 and MBOAT7 risk groups
MASH with moderate to advanced fibrosis (F2-F3)source ↗
●Equity OfferingCorporate
Grants of inducement equity awards to 26 new employees under Nasdaq Rule 5635(c)(4)
▲Patent GrantedResmetiromApprovedIP / Competition
USPTO issued new patent for Rezdiffra (F4c)
MASHsource ↗
▲Development Candidate NominationPreclinical
First drug candidate nominated in siRNA partnership for MASH
MASHsource ↗
●IND Enabling CompletePreclinical
Initiation of IND-enabling studies for siRNA candidate in MASH
MASHsource ↗
▲Development Candidate NominationPreclinical
First candidate drug nomination milestone achieved in siRNA partnership for MASH
MASHsource ↗
●IND Enabling CompletePreclinical
Immediate initiation of IND-enabling studies following candidate nomination
MASHsource ↗
▲Patent GrantedResmetiromApprovedIP / Competition
USPTO issued three new resmetirom patents including F4c patent
MASHsource ↗
▲Patent GrantedResmetiromApprovedIP / Competition
U.S. Patent No. 12,667,575 issued for weight-threshold step-down dosing with moderate CYP2C8 inhibitor
F2/F3 MASHsource ↗
▲Quarterly UpdateResmetiromApprovedCorporate
Q2 2026 Rezdiffra net sales of $364.3 million
MASHsource ↗
▲Patent GrantedResmetiromApprovedIP / Competition
U.S. Patent No. 12,661,361 issued for method of treating well-compensated cirrhosis (F4c)
well-compensated cirrhosis (F4c)source ↗
◆Oral PresentationPresentation
Madrigal to present at Goldman Sachs Health Care Conference 2026
▲First Patient DosedMGL-2086Trial
First healthy volunteers dosed in Phase 1 SAD trial of MGL-2086
MASHsource ↗
◆Poster PresentationResmetiromApprovedPresentation
Poster on baseline ANTICIPATE score and response predicting liver outcome events in MASH cirrhosis cohort treated with resmetirom
MASH cirrhosis (F4c)source ↗
◆Oral PresentationResmetiromApprovedPresentation
Poster on Rezdiffra reducing Lp(a) and LDL-C at EASL Congress
MASHsource ↗
▲Partnership / LicenseMGL-0795Corporate
Licensing agreement with Arrowhead for global rights to ARO-PNPLA3
MASHsource ↗
▲Full ResultsMGL-0795Clinical Data
Phase 1 data published in NEJM showing 46% liver fat reduction in homozygous patients
MAFLDsource ↗
▲Oral PresentationResmetiromApprovedPresentation
Data presentations at EASL Congress in May
MASHsource ↗
●Pipeline PrioritizationMGL-0795Corporate
Addition of MGL-0795 (formerly ARO-PNPLA3), a clinical-stage siRNA targeting PNPLA3, to Madrigal's pipeline
MASHsource ↗
▲Enrollment UpdateResmetiromApprovedTrial
More than 42,250 patients on Rezdiffra as of March 31, 2026
MASHsource ↗
◆Oral PresentationPresentation
Madrigal to present at TD Cowen 46th Annual Health Care Conference
▲Partnership / LicenseCorporate
Licensed global rights to six pre-clinical siRNA programs for MASH
MASHsource ↗
▲Partnership / LicenseervogastatCorporate
Exclusive global license agreement for ervogastat, a phase 2 oral DGAT-2 inhibitor
MASHsource ↗
▲Partnership / LicenseCorporate
Exclusive global licensing agreement for six preclinical siRNA programs
MASHsource ↗
▲Pipeline PrioritizationCorporate
Expanded pipeline with global rights to six preclinical siRNA programs
MASHsource ↗
▲Partnership / LicenseervogastatCorporate
Exclusive global license agreement with Pfizer for ervogastat
MASHsource ↗
▲Oral PresentationResmetiromApprovedPresentation
Two-Year Time Course of Biomarker and Imaging Responses in Well-Compensated MASH Cirrhosis Patients Treated with Resmetirom
compensated MASH cirrhosis (F4c)source ↗
▲Poster PresentationResmetiromApprovedPresentation
Durability of Resmetirom Response in MASLD Patients After Two Years of Treatment in MAESTRO-NAFLD-OLE
MASH with moderate to advanced fibrosissource ↗
◆Oral PresentationResmetiromApprovedPresentation
New analyses from open-label compensated MASH cirrhosis (F4c) arm of MAESTRO-NAFLD-1 trial
MASHsource ↗
◆Poster PresentationResmetiromApprovedPresentation
Multiple posters on early real-world experience with Rezdiffra, regression of MASH biomarkers when treatment interrupted, and burden of uncontrolled MASH
MASHsource ↗
Past FDA Catalysts and PDUFA Decisions
How MDGL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-11-09 | Rezdiffra (resmetirom) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 18%
Mid Cap(rank 124 of 687)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Rezdiffra |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Resmetirom Small MoleculesMarketedNCT05500222 | NASH | Approved | ACTIVE NOT_RECRUITING | 845 | Jan 1, 2027 | ||||||
| Resmetirom Small MoleculesMarketedNCT03900429 | NASH - Nonalcoholic Steatohepatitis | Approved | ACTIVE NOT_RECRUITING | 1,759 | Jan 1, 2028 | ||||||
| Resmetirom Small MoleculesNCT04951219 | Non-Alcoholic Fatty Liver Disease | Phase 3 | ACTIVE NOT_RECRUITING | 2,153 | Apr 1, 2027 | ||||||
| Resmetirom Small MoleculesMarketedNCT07763015 | MASH | Approved | RECRUITING | 61 | Jul 1, 2029 | ||||||
| Resmetirom Small MoleculesMarketedNCT07830758 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Approved | RECRUITING | 210 | Dec 1, 2027 | ||||||
| Resmetirom Small MoleculesMarketedNCT02912260 | Non-alcoholic Steatohepatitis | Approved | COMPLETED | 125 | Nov 23, 2021 | ||||||
| Resmetirom Small MoleculesNot countedNCT03038022 | Heterozygous Familial Hypercholesterolemia | Phase 2 | COMPLETED | 116 | Jan 15, 2018 | ||||||
| Resmetirom Small MoleculesNot countedNCT04643795 | Hepatic Impairment | Phase 1 | COMPLETED | 87 | Aug 4, 2021 | ||||||
| Resmetirom Small MoleculesNot countedNCT06397872 | Renal Impairment | Phase 1 | COMPLETED | 28 | Dec 31, 2024 | ||||||
| VIA-3196 Small MoleculesNot countedNCT01519531 | Drug Safety | Phase 1 | COMPLETED | 120 | Nov 1, 2012 |
Clinical Trial Results
Readouts, endpoints and source filings for every MDGL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Rezdiffra | metabolic dysfunction-associated steatohepatitis (MASH) | 2026-11-05 | 93%; 72%; 37% to 55%; 55%; 48.0%; 88%; 45%; 38%; 89%Read More | Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with RezdiffraRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kelley Shannon TOfficer (General Counsel) | Sell | -1,077 10,397 held | $400.00 | 11/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MDGL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 5.8 % (-9.4 %) | 1.15 B | 2.14 M | 0.07% ( 1.43 K) |
Ownership Trends
MDGL Short Interest
Shares sold short, counted twice a month.
9.86%
Short % of Float
of tradable shares sold short
2.1M
Shares Sold Short
-2.6% vs prior count
7.6 High
Days to Cover
trading days of normal volume to buy every short share back
279.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MDGL ranks across every disease it competes in
Competitive Position is a premium feature
See how MDGL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMDGL News
MDGL▲ +0.5%today
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Madrigal Pharmaceuticals announced its participation in three upcoming investor conferences, including the Jefferies Global Healthcare Conference and the Piper Sandler Healthcare Conference. These events will feature live webcasts for investors. Madrigal's focus remains on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), with its drug Rezdiffra already approved for certain stages of the disease.
Read more →MDGLMadrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra
Madrigal Pharmaceuticals presented new real-world data on Rezdiffra at AASLD 2026, showing that 93% of patients experienced improvements in liver stiffness after one year. The studies indicated high treatment persistence, with 72% of patients remaining on the medication. Improvements in liver health markers were consistent across various patient demographics, reinforcing Rezdiffra's effectiveness and safety.
Read more →MDGL▼ -8.1%on this newsshared move
Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals reported strong third-quarter 2026 results, with Rezdiffra achieving blockbuster status and net sales of $431.3 million. The company also announced a new Phase 3 trial for well-compensated MASH cirrhosis, aiming to strengthen its market leadership. Madrigal's financial position remains robust, with $961.8 million in cash and equivalents.
Read more →MDGLMadrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
Madrigal Pharmaceuticals will present 13 abstracts on Rezdiffra at AASLD's The Liver Meeting 2026. These abstracts highlight real-world evidence demonstrating the drug's effectiveness and tolerability in treating metabolic dysfunction-associated steatohepatitis (MASH). The data includes insights from over 12,000 patients, reinforcing Rezdiffra's role as a foundational therapy for MASH.
Read more →MDGLMadrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
Madrigal Pharmaceuticals will announce its third-quarter 2026 financial results on November 3, 2026, before U.S. markets open. Following this, a live webcast will be held at 8 a.m. ET to discuss the financial and operational outcomes. The webcast will also be available for later viewing on the company's website.
Read more →MDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals announced the granting of equity inducement awards to 26 new non-executive employees as part of its 2025 Inducement Plan. These awards were approved by the independent Compensation Committee and are intended to incentivize new hires. The company continues to focus on its novel therapeutic, Rezdiffra, for treating metabolic dysfunction-associated steatohepatitis (MASH).
Read more →MDGLMadrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
Madrigal Pharmaceuticals announced a publication in the Journal of Hepatology detailing a secondary analysis of the Phase 3 MAESTRO-NASH trial. The analysis revealed that Rezdiffra effectively improves liver histology and biomarkers in patients with common genetic variants associated with metabolic dysfunction-associated steatohepatitis (MASH). This suggests that Rezdiffra's therapeutic effects are consistent across different genetic risk factors.
Read more →MDGLMadrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
Madrigal Pharmaceuticals will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026. The event will feature a live webcast of the presentation, which will be accessible through their Investor Relations page. Madrigal is known for its innovative treatment, Rezdiffra, for metabolic dysfunction-associated steatohepatitis (MASH).
Read more →MDGLMadrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
Madrigal Pharmaceuticals has appointed Dr. John C. Reed to its Board of Directors. Dr. Reed brings significant experience from his role at Johnson & Johnson, where he led R&D efforts. His appointment is expected to enhance Madrigal's strategic leadership and support its growth in the metabolic dysfunction-associated steatohepatitis (MASH) sector.
Read more →MDGLMadrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
Madrigal Pharmaceuticals will participate in the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. The event will feature a live webcast of their presentation, which can be accessed through their Investor Relations page. Madrigal's focus is on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), with their drug Rezdiffra being a key product.
Read more →MDGL▼ -9.8%on this news
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals reported strong second-quarter 2026 financial results, with Rezdiffra net sales reaching $364.3 million, a 71% increase from the previous year. The company has also initiated a Phase 1 trial for MGL-2086, an oral GLP-1, to enhance MASH treatment options. Despite a net loss of $57.9 million, Madrigal's cash reserves remain robust at $838.9 million, supporting its ongoing development efforts.
Read more →MDGLMadrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
Madrigal Pharmaceuticals will announce its second-quarter 2026 financial results on July 30, 2026, before U.S. markets open. Following the announcement, a live webcast will be held at 8 a.m. ET to discuss the financial and operational results. The webcast will be accessible on the company's Investor Relations page.
Read more →MDGLMadrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
Madrigal Pharmaceuticals announced the issuance of three new patents for its drug, resmetirom, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). These patents include methods for treating well-compensated cirrhosis and reinforce protections for existing indications. The CEO highlighted the strategic importance of these patents in supporting innovation and maintaining leadership in the MASH market.
Read more →MDGLRibo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
Suzhou Ribo Life Science and Madrigal Pharmaceuticals have successfully achieved their first candidate drug nomination milestone in their siRNA partnership aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). This milestone will lead to the initiation of IND-enabling studies for planned clinical trials. The collaboration emphasizes their commitment to developing innovative RNA therapeutics for liver diseases.
Read more →About Madrigal Pharmaceuticals, Inc.
Headquarters1001 CONSHOHOCKEN STATE ROAD, WEST CONSHOHOCKEN, PA
BIOPHARMAWATCH ELITE
Trade the next MDGL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime